Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis B virus precore/core variation and interferon therapy

G Fattovich1, G McIntyre, M Thursz

  • 1Istituto Semeiotica e Nefrologica Medica, University of Verona, Italy.

Hepatology (Baltimore, Md.)
|November 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A multiomic framework for predicting laryngo-esophageal dysfunction following induction chemotherapy in hypopharyngeal-laryngeal carcinoma.

ESMO open·2025
Same author

A Sputtered Gig-Lox TiO<sub>2</sub> Sponge Integrated with CsPbI<sub>3</sub>:EuI<sub>2</sub> for Semitransparent Perovskite Solar Cells.

The journal of physical chemistry. C, Nanomaterials and interfaces·2025
Same author

A multicenter retrospective analysis of recurrent/metastatic nasopharyngeal cancer from non-endemic areas: Results in the pre-immunotherapy era.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Microbial players in autoimmunity: multicentric analysis of the association between <i>Mycoplasma hominis</i> serostatus and rheumatoid arthritis.

Microbiology spectrum·2025
Same author

Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study.

ESMO open·2024
Same author

Changes in body composition in early breast cancer patients treated with aromatase inhibitors.

Journal of endocrinological investigation·2024

Hepatitis B precore and core gene mutations were analyzed for interferon treatment response. Pretreatment core gene variations, not precore mutations, may predict treatment success in hepatitis B patients.

Area of Science:

  • Hepatology
  • Virology
  • Molecular Biology

Background:

  • Hepatitis B e antigen (HBeAg) and antibody to HBeAg (anti-HBe) status are key indicators in chronic hepatitis B.
  • Interferon therapy is a treatment option for chronic hepatitis B, but response rates vary.
  • Viral genetic factors, including precore and core gene mutations, may influence treatment outcomes.

Purpose of the Study:

  • To investigate the correlation between precore/core gene sequences and interferon treatment response in patients with chronic hepatitis B.
  • To determine if pretreatment viral genotypes predict response to interferon therapy.
  • To assess the impact of viral mutations emerging during treatment on treatment efficacy and viral clearance.

Main Methods:

  • Analysis of precore/core gene sequences from HBeAg-positive and anti-HBe-positive patients before and after interferon treatment.

Related Experiment Videos

  • Detection of precore stop codon mutants and core protein amino acid substitutions.
  • Comparison of mutation frequencies between responders, nonresponders, and reactivators.
  • Assessment of viral load using polymerase chain reaction (PCR) in relation to mutation status.

    • Main Results:

    • Pretreatment, no precore stop codon mutants were found in HBeAg-positive responders or nonresponders. Precore mutants did not influence response in anti-HBe-positive patients.
    • Core protein variability was not significant in HBeAg-positive patients but was observed in anti-HBe-positive cases, with fewer substitutions in responders.
    • Precore mutants were more frequent in natural seroconverters than in interferon-induced seroconverters. Emergence of precore mutants during therapy correlated with ongoing viremia and treatment failure.

    Conclusions:

    • Pretreatment core gene sequences, but not precore sequences, may predict interferon response in hepatitis B.
    • The appearance of precore mutants during interferon therapy typically indicates failure to clear the virus.
    • Core protein substitutions during therapy do not appear to influence the outcome of interferon treatment.